Search by Drug Name or NDC
NDC 71335-1086-05 Benazepril Hydrochloride 20 mg/1 Details
Benazepril Hydrochloride 20 mg/1
Benazepril Hydrochloride is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bryant Ranch Prepack. The primary component is BENAZEPRIL HYDROCHLORIDE.
MedlinePlus Drug Summary
Benazepril is used alone or in combination with other medications to treat high blood pressure. Benazepril is in a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It works by decreasing certain chemicals that tighten the blood vessels, so blood flows more smoothly. High blood pressure is a common condition, and when not treated it can cause damage to the brain, heart, blood vessels, kidneys, and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 71335-1086-05Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Benazepril
Product Information
| NDC | 71335-1086 |
|---|---|
| Product ID | 71335-1086_fc9d1bd9-f945-7c61-e053-6294a90a3117 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | Benazepril Hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Benazepril Hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 20 |
| Active Ingredient Units | mg/1 |
| Substance Name | BENAZEPRIL HYDROCHLORIDE |
| Labeler Name | Bryant Ranch Prepack |
| Pharmaceutical Class | Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Decreased Blood Pressure [PE] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA076820 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 71335-1086-05 (71335108605)
| NDC Package Code | 71335-1086-5 |
|---|---|
| Billing NDC | 71335108605 |
| Package | 14 TABLET in 1 BOTTLE (71335-1086-5) |
| Marketing Start Date | 2022-05-04 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |